The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Mesenchymal stem cell therapy: Two steps forward, one step back
Open accessAbstract
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Mesenchymal stem cells reside in virtually all post-natal organs and tissues
Meirelles, L. D. S., Chagastelles, P. C., & Nardi, N. B. (2006) · Journal of Cell Science · doi:10.1242/jcs.02932 · Cited by 2,485
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364
Phinney, D. G., & Prockop, D. J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0637 · Cited by 1,908
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Fibroblast precursors in normal and irradiated mouse hematopoietic organs.
Friedenstein, A. J., Jf, G., & Nn, K. (1976) · PubMed · Cited by 1,658
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Self-citationStem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Biomaterial based modulation of macrophage polarization: a review and suggested design principles
Sridharan, R., Cameron, A. R., Kelly, D. J., Kearney, C. J., & O’Brien, F. J. (2015) · Materials Today · doi:10.1016/j.mattod.2015.01.019 · Cited by 826
Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease
Ranganath, S. H., Levy, O., Inamdar, M. S., & Karp, J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.005 · Cited by 809
Self-citationMesenchymal stem cell: An efficient mass producer of exosomes for drug delivery
Yeo, R. W. Y., Lai, R. C., Zhang, B., Tan, S. S., Yin, Y., Teh, B. J., & Lim, S. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.001 · Cited by 746
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application
Wang, M., Yuan, Q., & Xie, L. (2018) · Stem Cells International · doi:10.1155/2018/3057624 · Cited by 505
Lai, R. C., Tan, S. S., Teh, B. J., Sze, S. K., Arslan, F., de Kleijn, D. P., Choo, A., & Lim, S. K. (2012) · International Journal of Proteomics · doi:10.1155/2012/971907 · Cited by 485
Turturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483
“MSCs are currently the most widely studied stem cells, and in 2010 there were more than 100 registered clinical trials using these cells (9).”
BackgroundSun, Y., Shi, H., Yin, S., Ji, C., Zhang, X., Zhang, B., Wu, P., Shi, Y., Mao, F., Yan, Y., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07643 · Cited by 460
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440
Self-citationMSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation
Kean, T. J., Lin, P., Caplan, A. I., & Dennis, J. E. (2013) · Stem Cells International · doi:10.1155/2013/732742 · Cited by 433
Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices
Sharma, R. R., Pollock, K., Hubel, A., & McKenna, D. (2014) · Transfusion · doi:10.1111/trf.12421 · Cited by 430
Mesenchymal stem cell effects on T-cell effector pathways
Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt75 · Cited by 430
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy
Glenn, J. D. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.526 · Cited by 406
Carosella, E. D., Rouas-Freiss, N., Roux, D. T.-L., Moreau, P., & LeMaoult, J. (2015) · Advances in Immunology · doi:10.1016/bs.ai.2015.04.001 · Cited by 395
Moll, G., Alm, J. J., Davies, L. C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., Hamad, O. A., Hinsch, R., Ignatowicz, L., Locke, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1729 · Cited by 381
Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
Moll, G., Rasmusson-Duprez, I., von Bahr, L., Connolly-Andersen, A.-M., Elgue, G., Funke, L., Hamad, O. A., Lönnies, H., Magnusson, P. U., Sanchez, J., et al. (2012) · Stem Cells · doi:10.1002/stem.1111 · Cited by 357
Manufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Self-citationLiu, H., Peng, H., Wu, Y., Zhang, C., Cai, Y., Xu, G., Li, Q., Chen, X., Ji, J., Zhang, Y., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.048 · Cited by 339
Paracrine Effect of Mesenchymal Stem Cells Derived from Human Adipose Tissue in Bone Regeneration
Linero, I., & Chaparro, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107001 · Cited by 323
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
English, K., French, A., & Wood, K. J. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.009 · Cited by 303
Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies
Griffin, M. D., Ritter, T., & Mahon, B. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.156 · Cited by 289
Reconstructed Stem Cell Nanoghosts: A Natural Tumor Targeting Platform
Toledano Furman, N. E., Lupu-Haber, Y., Bronshtein, T., Kaneti, L., Letko, N., Weinstein, E., Baruch, L., & Machluf, M. (2013) · Nano Letters · doi:10.1021/nl401376w · Cited by 273
Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic Rats
Si, Y., Zhao, Y., Hao, H., Liu, J., Guo, Y., Mu, Y., Shen, J., Cheng, Y., Fu, X., & Han, W. (2012) · Diabetes · doi:10.2337/db11-1141 · Cited by 271
Jung, Y., Bauer, G., & Nolta, J. A. (2012) · STEM CELLS · doi:10.1002/stem.727 · Cited by 270
Tissue repair and regeneration with endogenous stem cells
Xia, H., Li, X., Gao, W., Fu, X., Fang, R. H., Zhang, L., & Zhang, K. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0027-6 · Cited by 268
Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy
Krampera, M., & Le Blanc, K. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.006 · Cited by 260
Jarmalavičiūtė, A., Tunaitis, V., Pivoraitė, U., Venalis, A., & Pivoriūnas, A. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.07.013 · Cited by 259
MSCs: Biological characteristics, clinical applications and their outstanding concerns
Si, Y.-L., Zhao, Y.-L., Hao, H.-J., Fu, X.-B., & Han, W.-D. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.005 · Cited by 259
An, S. Y., Jang, Y. J., Lim, H.-J., Han, J., Lee, J., Lee, G., Park, J. Y., Park, S.-Y., Kim, J. H., Do, B.-R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.003 · Cited by 193
Kwon, Y. W., Heo, S. C., Jeong, G. O., Yoon, J. W., Mo, W. M., Lee, M. J., Jang, I.-H., Kwon, S. M., Lee, J. S., & Kim, J. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.002 · Cited by 137
Nooshabadi, V. T., Mardpour, S., Yousefi‐Ahmadipour, A., Allahverdi, A., Izadpanah, M., Daneshimehr, F., Ai, J., Banafshe, H. R., & Ebrahimi‐Barough, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26726 · Cited by 133
Nonmyogenic Cells in Skeletal Muscle Regeneration
Paylor, B., Natarajan, A., Zhang, R.-H., & Rossi, F. (2011) · Current Topics in Developmental Biology · doi:10.1016/b978-0-12-385940-2.00006-1 · Cited by 49
Ma, J., Li, Y., Chen, M., Wang, W., Zhao, Q., He, B., Zhang, M., & Jiang, Y. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09714-4 · Cited by 37
“Mesenchymal stem cells (MSCs) can differentiate into a variety of cell types, including osteoblasts, chondrocytes, and adipocytes, and are considered to be promising tissue remodeling therapeutic agents (Ankrum and Karp 2010).”
BackgroundUniversal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source
Carp, D. M., & Liang, Y. (2022) · Cells · doi:10.3390/cells11132077 · Cited by 29
“disease, graft versus host disease, myocardial infarction, stroke, acute lung injury, chronic obstructive pulmonary disease, cirrhosis, amyotrophic lateral sclerosis and diabetes, with the majority of patients receiving allogeneic MSCs [12,13].”
BackgroundHurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products
Childs, P. G., Reid, S., Salmeron-Sanchez, M., & Dalby, M. J. (2020) · Biochemical Journal · doi:10.1042/bcj20190382 · Cited by 27
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.835 · Cited by 23
Ghosh, S., & Ghosh, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878058 · Cited by 13
Kojima, H., Kushige, H., Yagi, H., Nishijima, T., Moritoki, N., Nagoshi, N., Nakano, Y., Tanaka, M., Hori, S., Hasegawa, Y., et al. (2023) · Cell Transplantation · doi:10.1177/09636897231170437 · Cited by 12
Zhang, R., Li, W., Jiang, X., Cui, X., You, H., Tang, Z., & Liu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863797 · Cited by 9
Metadata
- Authors
- Ankrum, J., & Karp, J. M.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 16
- Issue
- 5
- Pages
- 203-209
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2098459519
- Cited by
- 614
- References
- 51
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.